Welcome to the premier issue of Science Matters, the quarterly Discovery newsletter of Syngene International Ltd. I am pleased to introduce our organization to you. Syngene was founded in 1994 in Bengaluru, India. Over the years, Syngene expanded its capabilities to include nearly all the adjacencies required for therapeutic discovery, development, and manufacturing and became a publicly-traded company in August 2015.

From the Leader's Desk


Welcome to the premier issue of Science Matters, the quarterly Discovery newsletter of Syngene International Ltd. I am pleased to introduce our organization to you. Syngene was founded in 1994 in Bengaluru, India. Over the years, Syngene expanded its capabilities to include nearly all the adjacencies required for therapeutic discovery, development, and manufacturing and became a publicly-traded company in August 2015.


In addition to the broad range of expertise across the discovery and development paradigm, Syngene is further differentiated by the extent of our capabilities spanning multiple therapeutic areas and modalities. This includes traditional small molecules, therapeutic antibodies, antibody-drug conjugates, targeted protein degraders (heterobifunctionals and glues), and cell and gene therapy.


I hope you find our newsletter focused on Discovery services informative. Please feel free to share your views or write to us if you want to know more about a specific service/solution.


We would be delighted to hear from you.

Best Wishes,

Kenneth J. Barr, Ph.D.
Senior Vice President, Discovery Services
Syngene International

In the Spotlight


Analytical Chemistry services: Enabling accurate assessment of hit compounds


Syngene Analytical chemists apply a wide range of techniques to understand your hit compound structure and purity profile. This allows us to select and move your best candidate forward. Supporting us in these activities is our Analytical facility that has highly sensitive instruments to accurately measure APIs, conduct non-carry-over studies, facilitate structure elucidation, and undertake chiral and achiral separation from mg to >100 g scale.

Protein Degradation at Syngene


Accelerating PROTAC programs to drug the "undruggable"

 


PROteolysis TArgeting Chimeras (PROTACs) have garnered a lot of attention in recent times for their ability to exploit the cell's own degradation machinery to irreversibly degrade target proteins. In this point of view, we discuss how Syngene can help you move your PROTAC programs from hit to lead to the clinic with speed.

 

 

 
 

Sustainability at Syngene


Reducing environmental footprint the Syngene way


As a global CRO/CDMO, Syngene is leading the way in environmental sustainability through behavioral change and using new technology to improve performance continuously. Our Green Chemistry initiatives include paperless documentation, restricting toxic chemicals, reducing hazardous chemical usage, and more. In FY 2020-21, we recycled 80% of our operations hazardous and non-hazardous waste and 70% of the spent solvents generated from R&D activities.

Scientific Poster


In silico toxicity prediction using software-based screening methods


Syngene offers the best in-silico toxicity prediction tools and scientific expertise to help biopharma companies prioritize the right compounds to advance to the next stage. Here is a study we conducted with the Slovac Academy of Sciences for In silico toxicity prediction (skin sensitization, phototoxicity, hepatotoxicity, and invitro hERG inhibition) using Derek Nexus®.

 

 

 
 

Syngene Discovery Services Overview


Syngene offers integrated and standalone services across the drug discovery continuum from Target Identification to IND enabling.

© 2022, Syngene International Ltd.

Syngene International Ltd. Biocon Park, SEZ,

Bommasandra Industrial Area - Phase-IV Bangalore 560099 India